Karol M Pencina1, Arthur L Burnett2, Thomas W Storer1, Wen Guo1, Zhuoying Li1, Adam S Kibel3, Grace Huang1, Michelle Blouin1, Donna L Berry4, Shehzad Basaria1, Shalender Bhasin1. 1. Research Program in Men's Health: Aging and Metabolism, Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Boston, MA, USA. 2. Department of Urology, The Johns Hopkins University School of Medicine, The James Buchanan Brady Urological Institute, Baltimore, MD, USA. 3. Division of Urology, Brigham and Women's Hospital, Boston, MA, USA. 4. Department of Biobehavioral Nursing and Health Informatics, University of Washington, Seattle, WA, USA.
Abstract
BACKGROUND: Androgen deficiency is common among prostate cancer survivors, but many guidelines consider history of prostate cancer a contraindication for testosterone replacement. We determined the safety and efficacy of a selective androgen receptor modulator (OPK-88004) in symptomatic, testosterone-deficient men who had undergone radical prostatectomy for low-grade, organ-confined prostate cancer. METHODS: In this placebo-controlled, randomized, double-blind trial, 114 men, ≥19 years of age, who had undergone radical prostatectomy for low-grade, organ-localized prostate cancer, undetectable PSA (<0.1 ng/mL) for ≥2 years after radical prostatectomy and testosterone deficiency were randomized in stages to placebo or 1, 5, or 15 mg OPK-88004 daily for 12 weeks. Outcomes included PSA recurrence, sexual activity, sexual desire, erectile function, body composition, muscle strength and physical function measures, mood, fatigue, and bone markers. RESULTS: Participants were on average 67.5 years of age and had severe sexual dysfunction (mean erectile function and sexual desire domain scores 7.3 and 14.6, respectively). No participant experienced PSA recurrence or erythrocytosis. OPK-88004 was associated with a dose-related increase in whole-body (P < 0.001) and appendicular (P < 0.001) lean mass and a significantly greater decrease in percent body fat (P < 0.001) and serum alkaline phosphatase (P < 0.001) than placebo. Changes in sexual activity, sexual desire, erectile function, mood, fatigue, physical performance, and bone markers did not differ among groups (P = 0.73). CONCLUSIONS: Administration of OPK-88004 was safe and not associated with PSA recurrence in androgen-deficient men who had undergone radical prostatectomy for organ-confined prostate cancer. OPK-88004 increased lean body mass and decreased fat mass but did not improve sexual symptoms or physical performance.
BACKGROUND: Androgen deficiency is common among prostate cancer survivors, but many guidelines consider history of prostate cancer a contraindication for testosterone replacement. We determined the safety and efficacy of a selective androgen receptor modulator (OPK-88004) in symptomatic, testosterone-deficient men who had undergone radical prostatectomy for low-grade, organ-confined prostate cancer. METHODS: In this placebo-controlled, randomized, double-blind trial, 114 men, ≥19 years of age, who had undergone radical prostatectomy for low-grade, organ-localized prostate cancer, undetectable PSA (<0.1 ng/mL) for ≥2 years after radical prostatectomy and testosterone deficiency were randomized in stages to placebo or 1, 5, or 15 mg OPK-88004 daily for 12 weeks. Outcomes included PSA recurrence, sexual activity, sexual desire, erectile function, body composition, muscle strength and physical function measures, mood, fatigue, and bone markers. RESULTS: Participants were on average 67.5 years of age and had severe sexual dysfunction (mean erectile function and sexual desire domain scores 7.3 and 14.6, respectively). No participant experienced PSA recurrence or erythrocytosis. OPK-88004 was associated with a dose-related increase in whole-body (P < 0.001) and appendicular (P < 0.001) lean mass and a significantly greater decrease in percent body fat (P < 0.001) and serum alkaline phosphatase (P < 0.001) than placebo. Changes in sexual activity, sexual desire, erectile function, mood, fatigue, physical performance, and bone markers did not differ among groups (P = 0.73). CONCLUSIONS: Administration of OPK-88004 was safe and not associated with PSA recurrence in androgen-deficient men who had undergone radical prostatectomy for organ-confined prostate cancer. OPK-88004 increased lean body mass and decreased fat mass but did not improve sexual symptoms or physical performance.
Authors: Kimberly D Miller; Leticia Nogueira; Angela B Mariotto; Julia H Rowland; K Robin Yabroff; Catherine M Alfano; Ahmedin Jemal; Joan L Kramer; Rebecca L Siegel Journal: CA Cancer J Clin Date: 2019-06-11 Impact factor: 508.702
Authors: Upendram Srinivas-Shankar; Stephen A Roberts; Martin J Connolly; Matthew D L O'Connell; Judith E Adams; Jackie A Oldham; Frederick C W Wu Journal: J Clin Endocrinol Metab Date: 2010-01-08 Impact factor: 5.958
Authors: Sarah Acaster; Rene Dickerhoof; Kendra DeBusk; Kristine Bernard; William Strauss; Lee F Allen Journal: Health Qual Life Outcomes Date: 2015-05-17 Impact factor: 3.186
Authors: Katherine S Ruth; Felix R Day; Jessica Tyrrell; Deborah J Thompson; Anna Murray; Ken K Ong; Timothy M Frayling; John R B Perry; Andrew R Wood; Anubha Mahajan; Robin N Beaumont; Laura Wittemans; Susan Martin; Alexander S Busch; A Mesut Erzurumluoglu; Benjamin Hollis; Tracy A O'Mara; Mark I McCarthy; Claudia Langenberg; Douglas F Easton; Nicholas J Wareham; Stephen Burgess Journal: Nat Med Date: 2020-02-10 Impact factor: 53.440
Authors: Wen Guo; Karol M Pencina; Jeremy D Furtado; Frank M Sacks; Tomas Vaisar; Ming Cheng; Allan D Sniderman; Stephanie T Page; Shalender Bhasin Journal: J Endocr Soc Date: 2022-06-28